Cite
A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma.
MLA
Held, Lauren A., et al. “A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma.” Cancer Investigation, vol. 31, no. 3, Mar. 2013, pp. 172–76. EBSCOhost, https://doi.org/10.3109/07357907.2012.756109.
APA
Held, L. A., Rizzieri, D., Long, G. D., Gockerman, J. P., Diehl, L. F., Castro, C. M. de, Moore, J. O., Horwitz, M. E., Chao, N. J., & Gasparetto, C. (2013). A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Investigation, 31(3), 172–176. https://doi.org/10.3109/07357907.2012.756109
Chicago
Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. 2013. “A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma.” Cancer Investigation 31 (3): 172–76. doi:10.3109/07357907.2012.756109.